In vitro testing indicated that sorafenib may lead to paradoxical ERK activation in both wild-type BRAF and fusion KIAA1549:BRAF tumor cells as well as NF1-deficient cells, suggesting that BRAF inhibitors should only be used in BRAFV600E-mutant tumors [40]. Here, BRAF is linked to neoplasm.